1. "Sean Devlin"
Formats
  1. Meeting Abstract (365)
  2. Journal Article (215)
  3. Research Letter (14)
  4. Correspondence (5)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Biostatistics Service (601)
  2. Epidemiology and Biostatistics (601)
  3. Department of Medicine (574)
  4. Hematologic Malignancies, Division of (573)
  5. Center for Hematologic Malignancies (570)
  6. Bone Marrow Transplant (457)

More Groups

People
  1. Sean Devlin (601)
  2. Sergio Giralt (372)
  3. Miguel-Angel Perales (293)
  4. Gunjan Shah (177)
  5. Molly Maloy (162)
  6. Parastoo Dahi (155)

More People

Years
  1. 2025 (13)
  2. 2024 (25)
  3. 2023 (52)
  4. 2022 (42)
  5. 2021 (36)
  6. 2020 (56)

More Years

Publications
  1. Blood (194)
  2. Biology of Blood and Marrow Transplantation (133)
  3. Bone Marrow Transplantation (51)
  4. Blood Advances (28)
  5. Transplantation and Cellular Therapy (25)
  6. Journal of Clinical Oncology (15)

More Publications

Publishers
  1. American Society of Hematology (222)
  2. Elsevier Inc. (175)
  3. Nature Publishing Group (73)
  4. Taylor & Francis Group (16)
  5. American Society of Clinical Oncology (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (601)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management
    Journal Article

    Pennisi, M.; Jain, T.; Santomasso, B. D.; Mead, E.; Wudhikarn, K.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Devlin, S. M.; Batlevi, C.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: A Tri-State Transplant Consortium study
    Correspondence

    Hassoun, H.; Bayer, R.; Devlin, S.; Gentile, T.; Becker, M.; O’Dweyer, K.; Lesser, M.; Landau, H.; Chung, D.; Giralt, S.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies
    Journal Article

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Shahrokni, A.; Jakubowski, A. A.; Dahi, P. B.; Perales, M. A.; Tamari, R.; Shaffer, B. C.; Sauter, C. S.; more...
    Bone Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis
    Journal Article

    Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
    Journal Article

    Soff, G. A.; Mones, J.; Wilkins, C.; Devlin, S.; Haegler-Laube, E.; Wills, J.; Sarasohn, D. M.; Juluru, K.; Singer, M.; Miao, Y.; more...
    Research and Practice in Thrombosis and Haemostasis (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: A phase II study
    Meeting Abstract

    Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; King, A. C.; Stein, E. M.; Pemmaraju, N.; Mauro, M. J.; Kadia, T. M.; Montalban-Bravo, G.; Alvarez, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Blood (2019)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparing gradings of immune effector cells toxicities: Application of ASTCT consensus grading system and implications for clinical management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save